Bavarian Nordic
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Bavarian Nordic sits in the top decile of US sponsors by registered trial count (#429 of 15,742 sponsors by registered trial count).
Bavarian Nordic: 41 sponsored US clinical trials, 2 recruiting.
Bavarian Nordic sponsors 41 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 36 completed. 14 of these trials are in Phase 3-4 (later-stage) and 26 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Chikungunya Virus Infection, with 2 trials.
Top-decile sponsor footprint
Bavarian Nordic ranks in the top decile of sponsors by registered trial count (#429 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
36 of 37 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (97.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
41 total, page 1 of 1
Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells
NCT07199569
A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.
NCT07003984
A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine
NCT06899802
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination
NCT06007183
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2
NCT05329220
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years
NCT05349617
MVA-BN-RSV Vaccine Trial
NCT05238025
A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine
NCT05065983
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)
NCT05072080
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer
NCT04246671
A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer
NCT04134312
Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)
NCT03992872
Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects
NCT04131595
Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial
NCT03699124
BN Brachyury and Radiation in Chordoma
NCT03595228
CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
NCT03628716
Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults
NCT03483961
Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury)
NCT03349983
VAXCHORA Pediatric Study to Assess Safety and Immunogenicity
NCT03220737
A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer
NCT02840994
RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults
NCT02873286
Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers
NCT02391909
Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine
NCT02419391
A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults
NCT02100631
A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults
NCT02094586
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
NCT02038881
Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera
NCT01895855
A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects
NCT01668537
A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects
NCT01144637
Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200
NCT01585181
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
NCT01322490
A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy
NCT01152398
Special Access Program IMVAMUNE®
NCT03472014
A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects
NCT00857493
Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects
NCT00623259
A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer
NCT00629057
A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer
NCT00485277
A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis
NCT00316602
Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients
NCT00316589
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients
NCT00189904
PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
NCT00078585
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 14 |
| Phase 3 | 12 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the Bavarian Nordic pipeline
2 recruiting of 41 indexed (5% open); 36 completed (88%).
Phase mix: 14 late (III/IV) vs 26 early (I/II) (early-phase heavy).
Top condition: Chikungunya Virus Infection (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Bavarian Nordic: open-pipeline peers nationwide
Peers matched on 41 registered trials and 5% open enrollment, not the therapeutic-area sidebar.
Bavarian Nordic sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 41 trials (± recruiting share)
- Friends Research Institute · 41 trials · 12% recruiting
- Scripps Translational Science Institute · 41 trials · 20% recruiting
- Solventum US · 41 trials · 5% recruiting
- United States Naval Medical Center, San Diego · 41 trials · 15% recruiting
Sponsors near 5% open enrollment (± trial volume)
- Christiana Care Health Services · 5% recruiting · 82 trials
- Ferring Pharmaceuticals · 5% recruiting · 83 trials
- Amphastar Pharmaceuticals · 5% recruiting · 21 trials
- Cook County Health · 5% recruiting · 21 trials
Related
What to do with this Bavarian Nordic page
41 registered trials is a research-attention snapshot, not an endorsement of Bavarian Nordic or any single study.
- 2 of Bavarian Nordic's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Chikungunya Virus Infection is the condition Bavarian Nordic studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Chikungunya Virus Infection trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Bavarian Nordic pipeline card: 41 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.